Judge orders Highway 101 widening project EIR to be redrafted
A Santa Barbara County Superior Court judge ruled that part of the Highway 101 Widening Project Environmental Impact Report needs to be recalculated, but the decision is not expected to significantly delay the project. The estimated $428 million fourth stage of the undertaking includes adding high occupancy vehicle lanes in both directions through the 10.3-mile Read More →
Plains accused of misleading oil spill victims into signing away rights
Plains All American Pipeline has allegedly been misleading those who seek compensation for losses they incurred following the Refugio oil spill, according to a motion filed in federal court on Dec. 15. The motion asserts that Plains is asking the claimants to forfeit the right to file or take part in any other claim in Read More →
Freska buys Oceanside avocado packing plant
Oxnard-based Freska Produce International has purchased an avocado packer, Harvest Time Produce of Oceanside, the company announced in a news release Dec. 17. The move by Freska, which already has a Mexican avocado program, will allow the company known for mangoes to use the Oceanside packing plant to become a year-round provider of avocados. Terms Read More →
Amgen increases dividend to $1 per share
Amgen increased its yearly dividend 27 percent this year to $1 per share. Previously, the dividend had been 79 cents per share for the Thousand Oaks-based biotech giant. Shares jumped after news of the 27-cent dividend broke. The announcement was made just after the markets closed at 1:11 p.m. Amgen closed the trading day up Read More →
Ceres plans to raise $6.7 million through public stock offering Dec. 17
Ceres, a Thousand Oaks-based agriculture-biotechnology company, priced shares at 40 cents each on Dec. 15 for its follow-on public offering on Dec. 17. Ceres plans to raise $6.7 million through the offering, which will be comprised of 600,000 shares of common stock, 6,460 shares of preferred stock convertible into 16,150,000 shares of common stock, and Read More →
Amgen reacquires rights to sell 3 drugs worldwide
Amgen reacquired all rights to sell three drugs worldwide on Dec. 14. The Thousand Oaks-based biotech giant said it reacquired the rights to Prolia, Vectibix and Xgeva in 48 ccountries from British pharmaceutical company GlaxoSmithKline. The agreement includes large countries like Australia, China and Brazil. Prolia is designed to raise bone density in people with Read More →
